Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

BMC Cancer · 2014 · PMC4302067 · PMID 25511923

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Gemcitabine given to advanced NSCLC patients without progression after first-line treatment with a gemcitabine-cisplatin combination significantly improved progression-free survival (PFS), compared to the best palliative care, but the trial did not reach statistical significance for overall survival (OS) [ 5 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.